Short Interest in Genprex, Inc. (NASDAQ:GNPX) Increases By 46.5%

Genprex, Inc. (NASDAQ:GNPXGet Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 634,600 shares, a growth of 46.5% from the November 30th total of 433,100 shares. Based on an average daily volume of 9,290,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 7.7% of the shares of the stock are sold short.

Genprex Stock Down 1.6 %

GNPX traded down $0.01 during trading on Monday, hitting $0.86. The company’s stock had a trading volume of 198,370 shares, compared to its average volume of 2,561,180. The business’s fifty day simple moving average is $1.43 and its 200 day simple moving average is $1.24. Genprex has a twelve month low of $0.28 and a twelve month high of $14.40.

Hedge Funds Weigh In On Genprex

A hedge fund recently raised its stake in Genprex stock. Armistice Capital LLC grew its holdings in Genprex, Inc. (NASDAQ:GNPXFree Report) by 122.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 218,000 shares of the company’s stock after buying an additional 120,132 shares during the period. Armistice Capital LLC owned 10.39% of Genprex worth $411,000 as of its most recent filing with the Securities & Exchange Commission. 14.05% of the stock is owned by hedge funds and other institutional investors.

About Genprex

(Get Free Report)

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.

Featured Stories

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.